CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31

Caris Life Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$30.71+0.15 (+0.49%)

Close on Oct 19, 2026

Earnings

Next report expected Nov 4, 2026, during market hours (estimated from past report dates)

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 5, 2026	During market hours	$263.70M	–	–
Q1 FY2026 Ended Mar 31, 2026	May 7, 2026	During market hours	$216.20M	–	–
Q4 FY2025 Ended Dec 31, 2025	Jan 12, 2026	Before market open	$281.00M	–	–
Q3 FY2025 Ended Sep 30, 2025	Nov 5, 2025	During market hours	$216.80M	$0.08	–
Q2 FY2025 Ended Jun 30, 2025	Aug 12, 2025	During market hours	$181.40M	$-7.97	–

Outlook given with results on Aug 5, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
clinical therapy selection volume growth	full year 2026	20% growth	Maintained
revenue growth	full year 2026	27% to 28% growth	New
revenue	full year 2026	$1.03B to $1.04B	Raised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Announcements Caris Life Sciences filed with the SEC

Parsed from the XBRL in Caris Life Sciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CAI.

Revenue growth85.4% · median 27.5%

Operating margin15.5% · median -9.8%

Net margin10.6% · median -6.3%

Advertisement
300 × 250